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Abstract
Objectives—Individuals with bipolar disorder (BPD) exhibit alterations in their phospholipid
levels. It is unclear whether these alterations are a secondary consequence of illness state, or if
phospholipids and illness risk overlap genetically. If the latter were true, then phospholipids might
provide key insights into the pathophysiology of the illness. Therefore, we rank-ordered
phospholipid classes by their genetic overlap with BPD risk in order to establish which class might
be most informative in terms of increasing our understanding of illness pathophysiology.
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Methods—Analyses were conducted in a sample of 558 individuals, unselected for BPD, from
38 extended pedigrees (average family size=14.79, range=2–82). We calculated a coefficient of
relatedness for all family members of nine individuals with BPD in the sample (N=185); this
coefficient was set to be zero in unrelated individuals (N=373). Then, under an endophenotype
ranking value (ERV) approach, this scalar index was tested against 13 serum-based phospholipid
concentrations in order to rank-order lipid classes by their respective overlap with BPD risk.
Results—The phosphatidylinositol class was significantly heritable (h2=0.26, P=6.71 × 10−05). It
was the top-ranked class, and was significantly associated with BPD risk after correction for
multiple testing (β=−1.18, P=2.10 × 10−03, ERV=0.49).
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Conclusions—We identified a peripheral biomarker, serum-based phosphatidylinositol, which
exhibits a significant association with BPD risk. Therefore, given that phosphatidylinositol and
BPD risk share partially common etiology, it seems that this lipid class warrants further
investigation, not only in terms of treatment, but also as a promising diagnostic and risk marker.
Keywords
bipolar; family study; genetics; lipidome; phosphatidylinositol

1 INTRODUCTION
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Identifying endophenotypes for bipolar disorder (BPD) will garner greater understanding of
psychiatric illnesses, including BPD, which in turn will aid in their identification, diagnosis
and treatment.1–3 An endophenotype is a biomarker, or measurable characteristic, that is
associated with disease.4 Crucially, an endophenotype must share some appreciable portion
of its genetic etiology with disease risk.4 This requirement is important because it implies
that some portion of the biological processes that underlie the endophenotype overlap with
those that are disrupted in disease. Thus, the identification of endophenotypes for psychiatric
illnesses should contribute to our understanding of illness pathophysiology.5 Peripheral
markers, such as serum-based lipid measurements, hold great promise as endophenotypes
for two reasons. First, their underlying biochemical underpinnings are relatively well
understood, particularly when compared to, for example, brain-or behavior-based
phenotypes. Second, peripheral markers are easily obtainable at comparatively low cost.6
These advantages are particularly appealing for BPD, a psychiatric illness that is ranked as
one of the leading causes of disability and premature mortality worldwide,7–9 but whose
physiological underpinnings are still largely unknown.10
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Lipids and their polyunsaturated fatty acids (PUFAs) constitute basic and essential
components of all human cells, in terms of both structure, making up the major component
of cell membranes, and function, playing a part in neurotransmission, receptor function, and
eicosanoid biosynthesis.11,12 A number of lipidomic alterations have been noted in those
with BPD and also major depressive disorder (MDD).13 For example, increases in plasma
levels of lipid peroxidation have been noted in euthymic adults with BPD6 while decreases
have been noted in adolescent BPD individuals.14 It has been shown that essential PUFAs in
red blood cell membranes, including arachadonic and docosahexaenoic acid (DHA), are
reduced in BPD individuals in a manic phase15 and in individuals with MDD16, and that the
fatty acid composition of phospholipids in serum is altered in those with MDD such that the
arachadonic:eicosapentaenoic acid ratios are higher.17,18 Accordingly, a handful of studies
suggest that administration of fatty acids may have benefits in the amelioration of mood
symptoms.19–21 Brain-based findings, both in vivo and in vitro, indicate significant
elevations of phosphatidylcholines in the prefontal cortex,22 significantly reduced choline in
the frontal lobe,23 and reduced DHA in the orbitofrontal cortex24 in BPD individuals. In
sum, there is evidence for alterations in phospholipids and their fatty acids in BPD and
MDD. The direction of those alterations is currently unclear, probably in part because of
heterogeneity in methods and patient populations, although a recent and large study on this
topic, which utilized plasma-based lipid levels, documented an inverse relationship between
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phospholipid levels and symptoms of depression.26 The present study is the first to examine
the influence of genetic liability for BPD on serum-based phospholipids.
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Phosphatidylinositol (PI) (a membrane phospholipid that plays a crucial role in cell
physiology and signaling27) and its phosphorylated products phosphoinositides (PtdIns) are
particularly interesting in the context of BPD, given that lithium (Li+), the first-line mood
stabilizer treatment for BPD,28 acts upon the PI signal transduction pathway.29 While there
is converging evidence for inositol phospholipid system dysfunction in BPD,30–38 more
work is necessary to clarify this relationship.39 Of course, given the link between
phospholipids and the mechanism of action of Li+, it is possible that alterations in lipid
levels arise as a secondary consequence of treatment for BPD. This is why establishing such
a peripheral marker as an endophenotype of BPD is particularly important, as alterations are
demonstrated as a function of genetic proximity to an affected individual, that is, in
unaffected relatives who are not exposed to bipolar treatment regimens.5 The implication is
that alterations in serum phospholipid levels arise as a consequence of shared etiology,
making them and their underlying biochemical mechanisms potentially promising diagnostic
and/or treatment targets for BPD.
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In the present study, we aimed to1 (1) provide evidence for shared etiology between
phospholipid concentrations and BPD risk, and2 (2) determine which phospholipid classes
might be the most informative when attempting to isolate potential diagnostic and treatment
targets for BPD. We took sum concentrations of 13 phospholipid classes in a sample of 558
Mexican American individuals from 38 randomly ascertained extended pedigrees, and
calculated mean-based endophenotype ranking values (ERVs)40 between each phospholipid
class and a broad BPD phenotype (incorporating BPD types I and II). We used this broad
BPD phenotype to increase the total number of included affected individuals, which in turn
reduces the noise associated with any single diagnosis and maximizes power.

2 METHODS
2.1 Participants
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Lipidomic and diagnostic data were available in 567 individuals from 38 pedigrees (average
family size=14.79, range=2–82). The sample was 64% female and had a mean age of 49.28
years (SD=13.34, range=27–97). The lipidomic data were collected as part of the San
Antonio Family Study (SAFS), and diagnostic data were also available in these same
individuals as part of assessments conducted in the Genetics of Brain Structure and Function
(GOBS) study. GOBS data collection occurred between 2006 and 2016. Of the 567
individuals, nine persons had received a BPD diagnosis (BPD types I (N=4) and II (N=5);
see Table 1 for additional diagnostic information). Affected individuals were excluded from
the analysis and therefore the analysis was performed in 558 individuals, comprising 185
participants related to an affected individual plus 373 unrelated participants (Table 2).
All participants were randomly selected from the community with the constraints that they
were of Mexican American ancestry, part of a large family, and lived in the San Antonio
region. All participants provided written informed consent in compliance with the
institutional review board at the University of Texas Science Center of San Antonio.
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2.2 Diagnostic assessment
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The Mini-International Neuropsychiatric Interview (MINI41), a semi-structured interview,
was administered to all participants. Interviews were conducted by masters-and doctoratelevel research staff, who had established reliability for diagnosing bipolar disorder (κ≥0.85).
Subjects who reported possible pathology were discussed in case conference meetings with
licensed psychologists and/or psychiatrists. Consensus diagnoses were determined using
available medical records, the MINI, and the interviewer’s narrative.
2.3 Lipid extraction and analysis procedure
The lipid extraction procedure used in this sample has been described in detail elsewhere.
Briefly, lipid extraction in the SAFS is part of an ongoing longitudinal observational
investigation comprising four phases of data collection during a 23-year period. The
lipidomic data used in the present study were collected during the first phase, between the
years 1992 and 1996. The order of the plasma samples was randomized prior to lipid
extraction and analysis for each cohort. Quality control plasma samples were included at a
ratio of 1:18. Total lipid extraction from a 10-mL aliquot of plasma was performed in a
single-phase chloroform:methanol (2:1) extraction.44

42,43
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Lipid analysis was performed using liquid chromatography–electrospray ionization tandem
mass spectrometry using an Agilent 1200 liquid chromatography system (Agilent
Technologies, Santa Clara, CA, USA) combined with an Applied Biosystems API 4000 Q/
TRAP mass spectrometer with a turbo-ionspray source (350 uC) and the Analyst 1.5 data
system.44 We have previously reported the use of precursor ion and neutral loss scans on
control plasma extracts to identify the predominant lipid species of the following
phospholipid classes: sphingomyelin (SM), phosphatidylcholine (PC),
alkylphosphatidylcholine [PC(O)], alkenylphosphatidylcholine [PC(P); plasmalogen],
lysophosphatidylcholine (LPC), lysoalkylphosphatidylcholine [LPC(O); lysoplatelet
activating factor], phosphatidylethanolamine (PE), phosphatidylinositol (PI),
phosphatidylserine (PS), and phosphatidylglycerol (PG).44–46
Multiple reaction monitoring (MRM) experiments were established for the major species of
each lipid class identified in plasma. Relative lipid amounts were calculated by relating the
peak area of each species to the peak area of the corresponding stable isotope or nonphysiological internal standard. Total lipid classes were calculated from the sum of the
individual lipid species within each class.43
2.4 Quantitative genetic analysis
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All genetic analyses were performed in SOLAR.47 SOLAR implements a maximum
likelihood variance decomposition to determine the proportion of variation in a phenotype
due to genetic and environmental influences by modeling the covariance amongst family
members as a function of genetic proximity. The simplest such decomposition is one where
the additive genetic contribution of a trait is indexed by the heritability, or h2. All lipid
classes were subject to univariate decomposition analysis to ensure that they were
significantly heritable.
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2.5 Genetic correlation between BPD and lipid classes: the mean-based endophenotype
ranking value (mERV)
The mean-based endophenotype ranking value (mERV) represents an extension of the ERV.
The ERV, an effect size ranging between 0 and 1, was developed for the purpose of formally
testing endophenotypic status of phenotypes and to rank phenotypes by their standardized
genetic covariance with a disease of interest; it is expressed as follows:
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where
is the heritability of disease risk, is the heritability of the endophenotype, and
G
ρ is the genetic correlation between the two.48 The mERV is an extension of the ERV to be
used when the disease of interest is not sufficiently common in the data. For details on the
derivation of the mERV, see Glahn et al.40 Briefly, the mERV leverages the many
coefficients of relationship that exist in extended-pedigree data. The coefficient of
relationship refers to the average number of alleles held in common between individuals; for
example, first-degree relatives (e.g. full siblings or parents) share on average 50% of their
alleles, second-degree relatives (e.g. grandparents or aunts/uncles) share 25%, third-degree
relatives (e.g. great-grandparents or great-aunts/-uncles) share 12.5%, and so on. Thus, it is
possible, given an individual with a disease, to index all other pedigree members by their
degree of relatedness to that individual. This scalar can then be used to perform a fixedeffect single-degree-of-freedom test, within the univariate variance components analysis
outlined above, providing an estimate of the standardized genetic covariance between the
potential endophenotype and illness risk. The mERV can then be used in the same way as
the ERV to rank potential endophenotypes by their degree of standardized genetic overlap
with illness risk. In the present paper, the mERV was applied to BPD and all available lipid
classes.
We Bonferroni-corrected α (=0.05) by the effective number of traits using the method
outlined by Cheverud;49 correcting for the total number of traits would be overly
conservative, given the extent to which they are all correlated with one another.50 Applying
this method to the pairwise genetic correlations between the 13 phospholipid classes reveals
that we have 10.36 effective traits, thus α=0.05/10.36=4.82 × 10−03.

Author Manuscript

We tested the potential influence of confounding variables, in particular BMI and major
depressive disorder (MDD), on all lipid classes. We tested the potential genetic overlap,
using a bivariate polygenic model, between the lipids and potential psychiatric and
metabolic confounds. We then included those covariates with a significant genetic overlap
with the lipid class, using a liberal threshold of P<.10 in order to increase confidence that
important covariates were included in the univariate polygenic model described above in
addition to the BPD coefficient of relationship (which was fixed in the model). We tested the
following variables that were collected at the time of blood sampling as part of the SAFS
assessment51: body mass index (BMI); diabetes status; ever had a heart attack; smoking
status; and hypertension status. In addition, we investigated the following variables from the
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GOBS assessment taken from the MINI41: any depressive disorder; any anxiety disorder;
any alcohol use disorder; any substance use disorder.

3 RESULTS
3.1 Family profiles
According to our consensus diagnoses, nine individuals met the criteria of our broad BPD
phenotype, four individuals met the criteria for BPD I and five met the criteria for BPD II.
Table 2 shows the mean age and percent female of each category of relatedness to an
affected individual, as well as the unrelated group. No two affected BPD individuals fell
within the same pedigree, but these individuals were related to 185 individuals (Table 2).
3.2 Indexing genetic relatedness between BPD liability and all lipid classes
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The heritabilities of all lipid classes are shown in Table 3, inspection of which indicates that
each class is significantly heritable. Also shown in Table 3 are the β estimates from the
mERV analysis along with the P-values, of which one withstood a multiple testing
correction, that for the PI class (β=−1.18, P=2.10 × 10−03, ERV=0.49); this class was
deemed to be significantly heritable (h2=0.26, SE=0.08, P=6.71 × 10−05).
3.3 Investigating the influence of potential confounds: metabolic and psychiatric
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Of the metabolic variables, only diabetes status (ρg=0.35, SE=0.15, P=.03) was significantly
associated with PI levels. None of the other metabolic covariates (including BMI,
hypertension, heart attack, and smoking status) were significantly associated with PI. Of the
psychiatric diagnoses, only alcohol use disorders was significantly associated with PI levels
(ρg=−0.58, SE=0.28, P=.04). None of the other psychiatric diagnoses (including depression,
anxiety and substance abuse) were significantly associated with PI. Thus, aside from
diabetes status and alcohol use disorders, given the lack of significant genetic overlap
between the other metabolic and psychiatric phenotypes, we assumed that we need not
covary for them when investigating the genetic overlap between BPD risk and PI. Most
notably, neither BMI nor major depression demonstrate a shared etiology with serum levels
of PI in the present sample, and accordingly neither is likely to be a confounding factor in
the association between BPD risk and PI that is present in the sample.
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After controlling for diabetes status (in addition to age, age2, sex, and their interactions),
first-degree relatives of affected individuals exhibited lower levels of PI than unaffected,
unrelated controls (Cohen’s d=−0.53), while second-to sixth-degree relatives exhibited
levels intermediate between those of first-degree relatives (Cohen’s d=0.46) and controls
(Cohen’s d=−0.52). The levels of PI in cases, unaffected relatives and unaffected unrelated
individuals are shown in Figure 1. In general, it appears that the PI levels vary as a function
of genetic proximity to an affected individual. It is important to note that cases were not
included in the analyses outlined above, and thus their seemingly anomalous PI levels
should not be of concern; firstly there are only nine cases and secondly their PI levels are
subject to confounding factors such as mood-stabilizing medication.
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4 DISCUSSION
In the present study, we investigated the relative genetic overlap between BPD risk and 13
phospholipid classes; this was in an effort to rank the phospholipids according to which
might be most informative when attempting to disentangle the etiology of BPD. To our
knowledge, this is the first study to investigate possible genetic overlap between BPD risk
and serum phospholipid levels. The existence of significant genetic overlap between BPD
risk and phospholipid levels, and more specifically between illness risk and PI, strongly
suggests that PI is not merely a secondary manifestation of either illness state or treatment
but rather an endophenotypic marker of the illness with the potential for aiding early
detection and diagnosis, as well as enhanced treatment regimens.
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Phosphatidylinositols are membrane phospholipids found mostly on the inner leaflet of the
cell and are characterized by an inositol ring, or head group, extending into the cytoplasm.52
Despite their relatively low abundance compared to other membrane lipids, it is the
metabolism of this phospholipid class which gives rise to second messengers which are
major contributors to the myriad aspects of cellular regulation that make up the PI signal
transduction pathway.53,54 PI is implicated in well-characterized signal transduction
pathways, alterations in the molecular components of which, in particular
Phosphatidylinositol 4,5-bisphosphate (PIP2) and protein kinase C levels, have been
previously associated with BPD.31,37,55–65 The present study, to our knowledge, is the first
to suggest a shared etiology between serum PI levels and risk for BPD. PI is a particularly
interesting candidate endophenotype for BPD given that lithium (Li+), a mood-stabilizing
drug and treatment of choice for BPD,66 is thought to act upon the PI signaling pathway.
The inositol-depletion hypothesis posits that lithium acts by preventing the production of PI
via inhibition of inositol monophosphatase, thereby limiting turnover of inositol in the cell.
29,66
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The direction of the relationship between BPD risk and PI in the present study was negative,
meaning that heightened risk for BPD was associated with low levels of the phospholipid.
This is the only study, to our knowledge, to assess phospholipid levels in serum in relation to
BPD risk. However, Demirkan and colleagues also showed a negative correlation between
plasma-based phospholipids (phosphatidylcholine and sphingomyelin) and symptoms of
depression and anxiety.26 Therefore, while our results are seemingly in keeping with the
previous literature, they are not necessarily what the inositol-depletion hypothesis might
predict, where Li+ theoretically works to decrease high levels of inositol in BPD subjects.
Of course, the present study, like that of Demirkan and colleagues,26 relies on peripheral
indices of lipid levels. This allows us only to speculate on the ways in which these findings
might be interpreted in the brain. There is surprisingly little information in the literature
regarding either the direct origin of PI in circulation or the relationship between levels in the
periphery and in the brain. Serum PI is likely hepatic in origin, as the majority of circulating
lipids in lipoproteins are generated from the liver. The level of PIs is dependent on the
availability of myo-inositol, which in turn is synthesized from glucose. The enzymes
responsible for all these steps are found in liver cells as well as other organs. There is
evidence to suggest that lipids and their fatty acids are shuttled to the brain from the liver,
where they play crucial roles in neuro-development, -inflammation and -protection.67–69
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Future work might attempt to determine the levels of phospholipids in the brain and even the
relationship between phospholipid levels in the brain and in the periphery. One such line of
research might utilize phosphorous-31 magnetic resonance spectroscopy (31P MRS), an
imaging method that allows non-invasive measurement of biological compounds (e.g.
phospholipids) in vivo. In BPD, this technique has been used to demonstrate significantly
reduced choline, indicating altered phospholipid metabolism, in the frontal lobe.23 The
phosphomonester (PME) signal in 31P MRS reflects the level of phosphocholine and
phosphoethanolamine in addition to choline and myo-inositol; 70 there is evidence to suggest
that the PME signal increases during manic states and decreases during depressed states.
33,71–73 Thus, in addition to the unknown relationship between phospholipid levels in the
periphery and brain, it is possible that a second level of complexity exists where levels in
both are affected by BPD illness phase. Evidence from post-mortem studies for phospholipid
alterations in the brain in BPD is mixed; in some studies, alterations in phospholipids and/or
their fatty acids have not been observed in BPD subjects versus controls,74–76 while in other
studies such alterations have been observed.24,77 There is little consistency in terms of the
focal brain region across these studies, which may explain the inconsistencies in the results.
In addition, it is possible that lipidomic abnormalities in relation to affective disorders may
be characterized differently in other ethnic populations. For example, non-Hispanic
populations exhibit altered lipidomic profiles and associated risk for myocardial infarcation
relative to Hispanics.78 Thus, overall, it is important that the generalizability of the findings
of the present study should be further tested in future research.
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In the present study, there was a gap in time between the collection of the lipidomic data and
the occurrence of the psychiatric assessments. There is relatively little known about the
longitudinal variability of serum phospholipid levels. There is evidence to suggest that
phospholipids vary as a function of age,43 and as a consequence we residualized the
phospholipid traits for age (in fact for age, age2, sex, and their interactions) at the time of
data collection. We consider this a potential strength of the study as it suggests that variation
in PI reflects an early etiological step in the development of BPD. We cannot investigate this
in detail in the present sample, with the limited number of affected cases available, but it is
possible that the present results hint that alterations in PI reflect an “at-risk” condition for
BPD. Certainly, longitudinal studies of other peripheral markers, in this case markers of
inflammation, support an etiological role of inflammation in risk for MDD.79–81
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Two potential criticisms might be leveled at the present study regarding the affected
individuals. The first criticism is that no two affected individuals with BPD occur in the
same family, thus negating the idea that genetic factors underlie the illness. However, the
heritability of BPD is not in question, having been established by numerous family-based
studies and large genome wide association studies previously.1 Also, it is not improbable
that no two affected individuals would be part of the same family. Rather, what we would
expect is that an individual with an affected relative would have an increased risk for
developing BPD compared to an individual without an affected relative. This risk may not
necessarily be represented phenotypically as the full manifestation of the disorder within the
relative’s lifetime (or indeed by the time of assessment), but may influence the expression of
phenotypes related to the disorder. The second criticism is that only nine affected individuals
were included in the present study, but importantly these individuals originated from
Bipolar Disord. Author manuscript; available in PMC 2018 February 05.
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extended pedigrees. Therefore, because the question under investigation in this study was
one of genetic liability, this sample, comprising multiple extended pedigrees encapsulating
many degrees of relatedness, provides the statistical power needed to adequately test
hypotheses about putative pleiotropy between phospholipids and BPD risk. Indeed, an
advantage of large, extended pedigrees such as this (where family sizes varied between 2
and 82 individuals) is that many unaffected relatives, encapsulating many degrees of
relatedness, are available for a small number of cases.40 That being said, in subsequent work
where we attempt to fine-tune our hypotheses regarding PI and its role in BPD, we may need
greater numbers of probands.
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The ERV is the product of three terms: the square root of the heritability of the
endophenotype, the square root of the heritability of the disease, and the absolute value of
the genetic correlation between the two. Similarly, the power of the ERV is a function of all
three of these components, in the same way that the power of a genetic correlation is. While
the heritability of the endophenotypes (i.e. the phospholipid class) can be directly estimated
in the present sample, the heritability of BPD cannot, given that we have nine affected
individuals. For a single endophenotype, the heritability of BPD is not identifiable (in the
statistical sense) with this method. However, in principle with enough endophenotypes, the
heritability of BPD may be estimable from the method due to the constraints on the
parameter spaces of both the heritability and the genetic correlation, but it would generally
be difficult to resolve. The total ERV, which our inference of genetic correlation/pleiotropy
is based upon, is well estimated in the design. One of the substantial benefits of this method
of calculating the ERV is that it does not require affected relatives of cases and thus is very
useful for studying genetic determinants (shared via endophenotypes) of low-frequency
diseases.
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In summary, the findings presented here highlight PI as having a significant genetic overlap
with BPD risk. While it has been previously demonstrated that those with BPD exhibit
altered levels of phospholipids, this is the first study to highlight a shared etiology between
BPD and phospholipids. It is unlikely that the association between PI and BPD risk in the
present study arose as an artifact of lithium treatment, as affected individuals were excluded
from all genetic analyses. Rather, the serum level of this lipid appears to vary in unaffected
individuals as a function of genetic relatedness to a BPD individual and therefore the present
study highlights the potential utility of serum-level measurements of PI as an indicator of
illness risk. Moreover, this study suggests that the well-characterized PI signaling pathway
may be an interesting avenue of research for BPD, potentially providing testable hypotheses
for research aiming to improve diagnostic markers and/or treatment targets for BPD.
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FIGURE 1.

Average phosphatidylinositol levels (inverse Guassian normalized) between groups after
controlling for age, age2, sex, any alcohol use disorder and diabetes status. [Colour figure
can be viewed at wileyonlinelibrary.com]
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TABLE 1

Author Manuscript

Clinical characteristics of the sample
Number in affected individuals
(N=9)

Author Manuscript

a

Number in related individuals
(N=185)

Number in unrelated individuals
(N=373)

Any depressive disordera

9

54

137

Any anxiety disordera

5

18

38

Any alcohol use disordera

6

77

113

Any substance use disordera

1

32

32

Diabetes medicationb

0

5

26

Lipid medicationb

0

1

6

Hypertension medicationb

0

8

27

Diabetes statusb

0

9

45

Heart attackb

0

1

2

Heart surgeryb

0

1

0

Smokerb

2

58

77

Collected at the time of Genetics of Brain Structure and Function (GOBS) assessment.

b

Collected at the time of lipid data collection.
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TABLE 2

Author Manuscript

Means (and standard deviations) for age and percentage of female individuals by degree of relatedness to an
individual with bipolar disorder
Degree of relatedness

N

Mean age (SD)

–

9

34.65 (4.05)

67

First

31

45.84 (13.12)

55

Second

21

56.29 (8.85)

76

Third

52

46.09 (12.16)

63

Fourth

40

45.26 (11.83)

45

Fifth

33

36.50 (7.16)

58

Sixth

8

42.82 (8.04)

50

373

51.66 (13.36)

67

Unrelated

% female
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TABLE 3

Author Manuscript

Heritability and degree of bipolar relatedness for all lipid classes

Author Manuscript

β (P-value)

ERV

Clinical covariates included*

0.26 (6.71×10−05)

−1.18 (2.10−03)

0.49

Any alcohol use disorder; diabetes status

LPE

0.19 (7.82×10−03)

−0.83 (0.03)

0.33

None

LPC

0.32 (3.10×10−11)

−0.70 (0.06)

0.27

None

PC(O)

0.40 (4.34×10−15)

0.54 (0.08)

0.20

Any anxiety disorder; any depressive disorder

PE

0.41 (8.69×10−14)

−0.43 (0.24)

0.17

Diabetes status

PC(P)

0.32 (1.58×10−04)

0.48 (0.21)

0.19

Any anxiety disorder

PG

0.38 (1.20×10−14)

−0.24 (0.12)

0.18

Diabetes status; any alcohol use disorder

LPC(O)

0.52 (1.84×10−10)

0.57 (0.70)

0.18

Diabetes status; BMI

PC

0.28 (3.00×10−11)

−0.24 (0.17)

0.10

Any alcohol use disorder; diabetes status; BMI

PS

0.34 (1.01×10−14)

0.21 (0.54)

0.08

Any substance use disorder; hypertension; smoker; BMI

SM

0.38 (1.17×10−14)

0.19 (0.94)

0.08

Smoker; any alcohol use disorder; any substance use disorder; any anxiety
disorder

PE(O)

0.38 (2.50×10−06)

0.16 (0.71)

0.06

Any depressive disorder

PE(P)

(6.96×10−09)

0.16 (0.70)

0.06

Any anxiety disorder; any depressive disorder

Lipid class

h2 (P-value)

PI

0.45

Bold indicates class surviving multiple testing correction.
BMI, body mass index; ERV, endophenotype ranking value; PI, phosphatidylcholine; LPE, lysophosphatidylethanolamine; LPC,
lysophosphatidylcholine; PC(O), alkylphosphatidylcholine; PE, phosphatidylethanolamine; PC(P), alkenylphosphatidylcholine; PG,
phosphatidylglycerol; LPC(O), lysoalkylphosphatidylcholine; PC, phosphatidylcholine; PS, phosphatidylserine; SM, sphingomyelin; PE(O),
alkylphosphatidylethanolamine; PE(P), alkenylphosphatidylethanolamine.

*

Threshold of P<.1.
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